| 82.22 0.67 (0.82%) | 02-17 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 98.87 |
1-year : | 115.48 |
| Resists | First : | 84.65 |
Second : | 98.87 |
| Pivot price | 82.33  |
|||
| Supports | First : | 81.36 |
Second : | 79.33 |
| MAs | MA(5) : | 81.67 |
MA(20) : | 82.52 |
| MA(100) : | 78.34 |
MA(250) : | 69.9 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 34.3 |
D(3) : | 24.9 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 85.73 | Low : | 53.95 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PBE ] has closed above bottom band by 45.7%. Bollinger Bands are 46.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 82.57 - 82.91 | 82.91 - 83.22 |
| Low: | 80.9 - 81.27 | 81.27 - 81.63 |
| Close: | 81.63 - 82.21 | 82.21 - 82.76 |
PBE is not a pure-play biotech fund, it goes beyond the scope of pure biotech firms and includes companies that benefit significantly from advances in biotech and genetic engineering. This causes PBE to differ from other biotech ETFs, therefore, it is important to note the funds portfolio before investing. Moreover, far from a plain-vanilla approach, PBE's underlying index uses a multifactor system (price momentum, earnings momentum, quality: ROE, asset turnover, FCF margin), management action, and value) to select 30 US stocks and weights them in tiers. The tiered weighting scheme creates a small-cap tilt. Top-ranked larger stocks receive 40% of index weight while the top-ranked smaller stocks are given 60%. The approach produces a unique portfolio of biotech and peripheral-industry companies. The fund is rebalanced and reconstituted quarterly starting each February. Prior to August 28, 2023, the fund traded under the name Invesco Dynamic Biotechnology & Genome ETF.
Wed, 11 Feb 2026
How Invesco Dynamic Biotechnology & Genome Etf (PBE) Affects Rotational Strategy Timing - Stock Traders Daily
Thu, 05 Feb 2026
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Yahoo Finance
Wed, 04 Feb 2026
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Yahoo Finance
Thu, 29 Jan 2026
RCS - Invesco Bnd Inc Plus - QuotedData's In The HotSeat Special - TradingView
Mon, 29 Sep 2025
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Yahoo Finance
Fri, 19 Sep 2025
Invesco Biotechnology & Geno Funds To Go Ex-Dividend On September 22nd, 2025 With 0.23409 USD Dividend Per Share - 富途牛牛
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|